$135.92
Insights on Masimo Corp
Revenue is up for the last 3 quarters, 455.3M → 548.9M (in $), with an average increase of 8.8% per quarter
Netprofit is up for the last 2 quarters, 10.6M → 33.9M (in $), with an average increase of 68.7% per quarter
In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 60.6%
In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 110.5%
0.4%
Downside
Day's Volatility :2.08%
Upside
1.69%
44.66%
Downside
52 Weeks Volatility :62.01%
Upside
31.35%
Period | Masimo Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 11.61% | -0.7% | 0.0% |
6 Months | 72.41% | 6.6% | 0.0% |
1 Year | -28.88% | 3.7% | -1.5% |
3 Years | -43.77% | 14.0% | -21.8% |
Market Capitalization | 7.3B |
Book Value | $25.85 |
Earnings Per Share (EPS) | 1.51 |
PE Ratio | 91.51 |
PEG Ratio | 4.73 |
Wall Street Target Price | 150.03 |
Profit Margin | 3.98% |
Operating Margin TTM | 10.42% |
Return On Assets TTM | 2.93% |
Return On Equity TTM | 6.03% |
Revenue TTM | 2.0B |
Revenue Per Share TTM | 38.79 |
Quarterly Revenue Growth YOY | -11.0% |
Gross Profit TTM | 1.1B |
EBITDA | 225.7M |
Diluted Eps TTM | 1.51 |
Quarterly Earnings Growth YOY | -0.16 |
EPS Estimate Current Year | 3.52 |
EPS Estimate Next Year | 3.91 |
EPS Estimate Current Quarter | 0.87 |
EPS Estimate Next Quarter | 0.73 |
What analysts predicted
Upside of 10.38%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 858.3M | ↑ 7.54% |
Net Income | 193.5M | ↑ 47.05% |
Net Profit Margin | 22.55% | ↑ 6.06% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 937.8M | ↑ 9.27% |
Net Income | 196.2M | ↑ 1.38% |
Net Profit Margin | 20.92% | ↓ 1.63% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 21.96% |
Net Income | 240.3M | ↑ 22.47% |
Net Profit Margin | 21.01% | ↑ 0.09% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 8.34% |
Net Income | 229.6M | ↓ 4.45% |
Net Profit Margin | 18.53% | ↓ 2.48% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.0B | ↑ 64.29% |
Net Income | 143.5M | ↓ 37.5% |
Net Profit Margin | 7.05% | ↓ 11.48% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.0B | ↑ 0.6% |
Net Income | 81.5M | ↓ 43.21% |
Net Profit Margin | 3.98% | ↓ 3.07% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 549.3M | ↓ 2.83% |
Net Income | 37.9M | ↑ 109.39% |
Net Profit Margin | 6.9% | ↑ 3.7% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 617.0M | ↑ 12.32% |
Net Income | 40.9M | ↑ 7.92% |
Net Profit Margin | 6.63% | ↓ 0.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 565.0M | ↓ 8.43% |
Net Income | 21.3M | ↓ 47.92% |
Net Profit Margin | 3.77% | ↓ 2.86% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 455.3M | ↓ 19.42% |
Net Income | 15.7M | ↓ 26.29% |
Net Profit Margin | 3.45% | ↓ 0.32% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 478.9M | ↑ 5.18% |
Net Income | 10.6M | ↓ 32.48% |
Net Profit Margin | 2.21% | ↓ 1.24% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 548.9M | ↑ 14.62% |
Net Income | 33.9M | ↑ 219.81% |
Net Profit Margin | 6.18% | ↑ 3.97% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 26.87% |
Total Liabilities | 185.8M | ↓ 8.64% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 20.9% |
Total Liabilities | 228.3M | ↑ 22.88% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 22.66% |
Total Liabilities | 304.9M | ↑ 33.58% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 10.19% |
Total Liabilities | 336.8M | ↑ 10.45% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.2B | ↑ 70.14% |
Total Liabilities | 1.9B | ↑ 455.79% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.0B | ↓ 5.27% |
Total Liabilities | 1.7B | ↓ 10.42% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↑ 3.22% |
Total Liabilities | 1.8B | ↑ 2.58% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.2B | ↑ 5.05% |
Total Liabilities | 1.9B | ↑ 3.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 2.96% |
Total Liabilities | 1.8B | ↓ 4.62% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.0B | ↓ 3.35% |
Total Liabilities | 1.7B | ↓ 4.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.0B | ↓ 0.51% |
Total Liabilities | 1.7B | ↑ 1.02% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.0B | ↑ 1.52% |
Total Liabilities | 1.7B | ↓ 2.53% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 239.5M | ↑ 312.21% |
Investing Cash Flow | -26.2M | ↓ 45.41% |
Financing Cash Flow | 25.8M | ↓ 723.01% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 221.6M | ↓ 7.47% |
Investing Cash Flow | -197.7M | ↑ 655.89% |
Financing Cash Flow | -9.3M | ↓ 136.23% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 211.0M | ↓ 4.82% |
Investing Cash Flow | -82.8M | ↓ 58.12% |
Financing Cash Flow | -54.3M | ↑ 481.51% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 264.8M | ↑ 25.5% |
Investing Cash Flow | -37.5M | ↓ 54.67% |
Financing Cash Flow | -122.4M | ↑ 125.39% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 29.5M | ↓ 88.86% |
Investing Cash Flow | -1.1B | ↑ 2718.35% |
Financing Cash Flow | 520.3M | ↓ 525.07% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 10.4M | ↑ 325.88% |
Investing Cash Flow | -7.7M | ↓ 99.23% |
Financing Cash Flow | 29.1M | ↓ 94.38% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.6M | ↓ 163.46% |
Investing Cash Flow | -22.8M | ↑ 196.1% |
Financing Cash Flow | -4.7M | ↓ 116.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 400.0K | ↓ 106.06% |
Investing Cash Flow | -11.1M | ↓ 51.32% |
Financing Cash Flow | -35.2M | ↑ 648.94% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 23.6M | ↑ 5800.0% |
Investing Cash Flow | -22.4M | ↑ 101.8% |
Financing Cash Flow | -4.9M | ↓ 86.08% |
Sell
Neutral
Buy
Masimo Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Masimo Corp | 2.38% | 72.41% | -28.88% | -43.77% | 11.55% |
Stryker Corporation | -5.1% | 24.37% | 15.51% | 30.88% | 86.41% |
Boston Scientific Corp. | 1.07% | 34.02% | 31.68% | 66.24% | 93.56% |
Edwards Lifesciences Corp. | -6.04% | 25.15% | 3.43% | -1.49% | 47.65% |
Abbott Laboratories | -5.82% | 10.82% | 1.68% | -14.96% | 43.26% |
Medtronic Plc | -5.47% | 8.78% | -3.15% | -37.3% | -6.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Masimo Corp | 91.51 | 91.51 | 4.73 | 3.52 | 0.06 | 0.03 | NA | 25.85 |
Stryker Corporation | 40.98 | 40.98 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.66 | 63.66 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 39.15 | 39.15 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.4 | 33.4 | 5.99 | 4.59 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.16 | 25.16 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Masimo Corp | Buy | $7.3B | 11.55% | 91.51 | 3.98% |
Stryker Corporation | Buy | $128.5B | 86.41% | 40.98 | 15.44% |
Boston Scientific Corp. | Buy | $100.1B | 93.56% | 63.66 | 11.18% |
Edwards Lifesciences Corp. | Buy | $54.2B | 47.65% | 39.15 | 23.36% |
Abbott Laboratories | Buy | $189.5B | 43.26% | 33.4 | 14.27% |
Medtronic Plc | Buy | $105.2B | -6.1% | 25.16 | 13.0% |
FMR Inc
BlackRock Inc
Vanguard Group Inc
Politan Capital Management LP
Capital Research Global Investors
Massachusetts Financial Services Company
masimo (nasdaq: masi) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. our work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life for more than 27 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. the result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making. masimo is for‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see. we're looking for people who can, do, and will make a difference. we think you'll like what you see.
Organization | Masimo Corp |
Employees | 3800 |
CEO | Mr. Joseph E. Kiani |
Industry | Health Technology |
Vanguard Ultra Short Bond Et
$135.92
-0.51%
Surgery Partners Inc
$135.92
-0.51%
Sl Green Realty Corp.
$135.92
-0.51%
Goldman Sachs Activebeta Int
$135.92
-0.51%
Allegro Microsystems, Inc.
$135.92
-0.51%
Cleanspark Inc
$135.92
-0.51%
Chart Industries Inc.
$135.92
-0.51%
Agree Realty Corp
$135.92
-0.51%
Joby Aviation Inc
$135.92
-0.51%